In a Phase II double-blind, randomized, placebo-controlled, 5-week study of 56 rheumatoid arthritis patients with Sativex (Blake et al 2006), employed nocturnal treatment only to a maximum of 6 sprays per evening (16.2 mg THC + 15 mg CBD). In the final treatment week, morning pain on movement, morning pain at rest, DAS-28 measure of disease activity, and SF-MPQ pain at present all favored Sativex over placebo (Table 1).

• Is there a batch number? You know how you check your raw chicken or bagged lettuce every time there's a recall to make sure the one you bought isn't going to make you sick? You should be able to do that with CBD products too. "This is a huge indicator as to whether they are following good manufacturing practices," says Beatty. "There should be a way to identify this product in case it was improperly made so the company can carry out a recall."
"The DEA followed up, in October 2001, with publication of an interpretive rule in the Federal Register explaining the basis of its zero-tolerance standard.63 It held that when Congress wrote the statutory definition of marijuana in 1937, it 'exempted certain portions of the Cannabis plant from the definition of marijuana based on the assumption (now refuted) that such portions of the plant contain none of the psychoactive component now known as THC.' Both the proposed rule (which was published concurrently with the interpretive rule) and the final 2003 rule gave retailers of hemp foods a date after which the DEA could seize all such products remaining on shelves. On both rules, hemp trade associations requested and received court-ordered stays blocking enforcement of that provision. The DEA’s interpretation made hemp with any THC content subject to enforcement as a controlled substance.
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
Cannabis sativa is extremely unusual in the diversity of products for which it is or can be cultivated. Popular Mechanics magazine (1938) touted hemp as “the new billion dollar crop,” stating that it “can be used to produce more than 25,000 products, ranging from dynamite to Cellophane.” Table 1 presents the principal products for which the species is cultivated in Europe, all of which happen to be based on fiber. This presentation stresses the products that hold the most promise for North America, which also include a considerable range of oilseed applications (Table 2; Fig. 1).
Molecular analytical techniques developed in the late 20th century are being applied to questions of taxonomic classification. This has resulted in many reclassifications based on evolutionary systematics. Several studies of Random Amplified Polymorphic DNA (RAPD) and other types of genetic markers have been conducted on drug and fiber strains of Cannabis, primarily for plant breeding and forensic purposes.[74][75][25][76][77] Dutch Cannabis researcher E.P.M. de Meijer and coworkers described some of their RAPD studies as showing an "extremely high" degree of genetic polymorphism between and within populations, suggesting a high degree of potential variation for selection, even in heavily selected hemp cultivars.[37] They also commented that these analyses confirm the continuity of the Cannabis gene pool throughout the studied accessions, and provide further confirmation that the genus consists of a single species, although theirs was not a systematic study per se.
Cannabis sativa L. subsp. sativa var. sativa is the variety grown for industrial use, while C. sativa subsp. indica generally has poor fiber quality and female buds from this variety are primarily used for recreational and medicinal purposes. The major differences between the two types of plants are the appearance, and the amount of Δ9-tetrahydrocannabinol (THC) secreted in a resinous mixture by epidermal hairs called glandular trichomes, although they can also be distinguished genetically.[59][61] Oilseed and fiber varieties of Cannabis approved for industrial hemp production produce only minute amounts of this psychoactive drug, not enough for any physical or psychological effects. Typically, hemp contains below 0.3% THC, while cultivars of Cannabis grown for medicinal or recreational use can contain anywhere from 2% to over 20%.[62]
Blessing and Haney agree that the current evidence suggests that CBD shows promise for helping to treat some illnesses. In June 2018, the Food and Drug Administration (FDA) approved the first cannabis-derived drug — Epidiolex, which contains purified CBD — to treat certain rare childhood seizure syndromes. However, much of the research on CBD is only in very early stages, and scientists still don’t know a lot about it — including whether it has negative long-term effects.
Thank you. I am 81 and started the CBD drops night and morning. I sleep better and no longer suffer the excruciating pain from diverticulitis. I saw somewhere that for my asthma I need the THC so got some (totally illegal here in South Africa). I think it is helping. The diagnosis of COPD was made some years ago and as a health psychologist I do all I can to remain healthy for my 97th birthday!! (Both my grandmother and greatgrandmother did so I believe I will too).
Short-term use of the drug impairs thinking and coordination. In long-term studies, teens who smoke marijuana have lower IQs later on, as well as structural differences in their brains, though scientists debate whether this is an effect of the drug or a result of habitual pot smokers seeking out less intellectually stimulating pursuits. A 2016 study on almost 300 students by the University of Montreal published in the journal Development and Psychopathology found that teens who start smoking around age 14 do worse on some cognitive tests by age 20 than non-smokers. They also have a higher school dropout rate. If they wait until age 17 to start, though, the smokers do not seem to have the same impairments, according to the study. 

The first of Berenson’s questions concerns what has long been the most worrisome point about cannabis: its association with mental illness. Many people with serious psychiatric illness smoke lots of pot. The marijuana lobby typically responds to this fact by saying that pot-smoking is a response to mental illness, not the cause of it—that people with psychiatric issues use marijuana to self-medicate. That is only partly true. In some cases, heavy cannabis use does seem to cause mental illness. As the National Academy panel declared, in one of its few unequivocal conclusions, “Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use, the greater the risk.”

In the Australian states of Tasmania, Victoria, Queensland, New South Wales, and most recently, South Australia, the state governments have issued licences to grow hemp for industrial use. The first to initiate modern research into the potential of cannabis was the state of Tasmania, which pioneered the licensing of hemp during the early 1990s. The state of Victoria was an early adopter in 1998, and has reissued the regulation in 2008.[75]

Toggle navigationNewsConditionsConditionsADHDAllergic rhinitisAlzheimer's diseaseAnxietyArthritisAsthmaAutismBowel cancerBreast cancerCancerChesty coughsChickenpoxChlamydiaCholesterolCoeliac diseaseCommon coldConstipationCOPDDepressionDiabetesDiverticulitisEpilepsyFatty liverFibromyalgiaGenital herpesGORD (reflux)GoutHaemorrhoidsHair lossHeart attackHepatitisHiatus herniaHigh blood pressureHIV and AIDSImpotenceMenopauseMigraineNeuropathic painOsteoporosisPainPeptic ulcersPneumoniaProstate cancerScabiesSchizophreniaSciaticaShinglesSinusitisSkin cancerStrokeThyroid gland disordersUrticaria (hives)Vaginal thrushVasectomyVertigoVulval problemsWhooping coughMedicinesMedicinesAugmentinAvilChlorsigDaklinzaDuromineEndepEndoneHarvoniLevlenLyricaMersyndolMetrogylPanadeine FortePanefcortelonePrimolutRestavitSovaldiStemetilViagraZentelFind a MedicineMedicines CentreSymptomsSymptomsBack painChildhood rashesCommon coldDepressionFeverFibromyalgiaHeart attackHeel painHerpesLeg acheLeg crampsSciaticaShinglesStrokeVaginal thrushVertigoMore symptomsLifestyleHealthy LifestyleAddictionsAlcoholCholesterolExerciseHealthy eatingHealthy WeightHeart healthImmunisationSleepSmokingStress Health Centres Nutrition & WeightSports & FitnessTools Medical Dictionary Medical Dictionary
The results of the three large European cohort studies have been confirmed in two smaller New Zealand birth cohorts. Arsenault and colleagues (2002) reported a prospective study of the relationship between adolescent cannabis use and psychosis in a New Zealand birth cohort (n = 759). They found a relationship between cannabis use by age 15 and an increased risk of psychotic symptoms by age 26. The relationship did not change when they controlled for other drug use, but it was no longer statistically significant after adjusting for psychotic symptoms at age 11. The latter probably reflected the small number of psychotic disorders observed in the sample. Fergusson et al. (2003) found a relationship between cannabis dependence at age 18 and later symptoms that included those in the psychotic spectrum reported at age 21 in the Christchurch birth cohort. Fergusson and colleagues adjusted for a large number of potential confounding variables, including self-reported psychotic symptoms at the previous assessment, other drug use and other psychiatric disorders, but whether the association represents a link between cannabis use and psychotic symptoms specifically, or more general psychiatric morbidity, remains unclear.
Professors William Emboden, Loran Anderson, and Harvard botanist Richard E. Schultes and coworkers also conducted taxonomic studies of Cannabis in the 1970s, and concluded that stable morphological differences exist that support recognition of at least three species, C. sativa, C. indica, and C. ruderalis.[68][69][70][71] For Schultes, this was a reversal of his previous interpretation that Cannabis is monotypic, with only a single species.[72] According to Schultes' and Anderson's descriptions, C. sativa is tall and laxly branched with relatively narrow leaflets, C. indica is shorter, conical in shape, and has relatively wide leaflets, and C. ruderalis is short, branchless, and grows wild in Central Asia. This taxonomic interpretation was embraced by Cannabis aficionados who commonly distinguish narrow-leafed "sativa" strains from wide-leafed "indica" strains.[73]
Zammit and colleagues’ findings were supported in a 3-year longitudinal study of the relationship between self-reported cannabis use and psychosis in a community sample of 4848 people in the Netherlands (van Os et al., 2002). Van Os and colleagues reported that cannabis use at baseline predicted an increased risk of psychotic symptoms during the follow-up period in individuals who had not reported psychiatric symptoms at baseline. There was a dose–response relationship between frequency of cannabis use at baseline and risk of psychotic symptoms during the follow-up period. These relationships persisted when they statistically controlled for the effects of other drug use. The relationship between cannabis use and psychotic symptoms was also stronger for cases with more severe psychotic symptoms.

I have to share this with you all, I live in Washington State where pot is legal to everyone of age except if your sign a Pain Contract. As we all know to well who suffer from chronic pain that taking or lowering our life saving pain medications is slowly killing us, but we need to all remember that our country and state and the CDC are all trying to save us from addiction. So to my ear, I heard on the radio an advertisement from a local pot shop on their quality products and then when you listen to it, then it goes on to say as fast as they can, it my lead to addiction, so use cautiously. WHAT, it may lead to addiction but those of us who tried everything else to ease our miserable pain to only find that pain medications is so far the only thing that gives us relief. But our government and states want to protect us from ourselves by taking away our much needed medications and in my state offer me instead marijuana that may cause addiction, I say that is so CRAZY! Let people young and old use marijuana either to get high or for help with medical conditions with the chance that they may become addicted to it but for me, who I have never ever abused my pain medications, we have to lower you because you could become addicted to it and it is dangerous for your health. I ask so if you lower me so low where I have to stay in bed all day because it hurts to much to walk and with my blood pressure up so high that I am a sitting duck for a stroke, that that isn’t unhealthy for me????? At least with the proper dosage that aids me to have some life is so much better for my health than not enough or not any. INSANITY TO THE FULLEST!
A chief argument that has been advanced in favor of developing hemp as a paper and pulp source has been that as a non-wood or tree-free fiber source, it can reduce harvesting of primary forests and the threat to associated biodiversity. It has been claimed that hemp produces three to four times as much useable fiber per hectare per annum as forests. However, Wong (1998) notes evidence that in the southern US hemp would produce only twice as much pulp as does a pine plantation (but see discussion below on suitability of hemp as a potential lumber substitute in areas lacking trees).
A limited number of studies have examined the effects of cannabis smoking on the respiratory system.[89] Chronic heavy marijuana smoking is associated with coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis.[69] The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease.[90] Short-term use of cannabis is associated with bronchodilation.[91] Other side effects of cannabis use include cannabinoid hyperemesis syndrome.[92]